World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 3180501

Number of visits today: 3346

Number of downloads: 2341095

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Cobeñas CJ, Bresso PS, Lombardi LL, Amoreo OR, Ruscasso JD, Spizzirri AP, Del C Suarez Â, Zalba JH, Rahman RC, Risso P. Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome. Pediatr Nephrol 2015;30:2115-9. [PMID: 26141929 DOI: 10.1007/s00467-015-3147-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]

For:

Cobeñas CJ, Bresso PS, Lombardi LL, Amoreo OR, Ruscasso JD, Spizzirri AP, Del C Suarez Â, Zalba JH, Rahman RC, Risso P. Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome. Pediatr Nephrol 2015;30:2115-9. [PMID: 26141929 DOI: 10.1007/s00467-015-3147-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]

Number	Citing Articles
1	Loos S, Oh J, van de Loo L, Kemper MJ, Blohm M, Schild R. Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2021. [PMID: 34046736 DOI: 10.1007/s00467-021-05108-6] [Reference Citation Analysis]
2	Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
3	Balestracci A, Capone MA, Meni Battaglia L, Toledo I, Martin SM, Beaudoin L, Balbaryski J, Gómez L. Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial. Pediatr Nephrol 2022. [PMID: 35166922 DOI: 10.1007/s00467-022-05474-9] [Reference Citation Analysis]
4	Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2019;34:1485-92. [PMID: 30058046 DOI: 10.1007/s00467-018-4025-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
5	Tanné C, Javouhey E, Boyer O, Recher M, Allain-launay E, Monet-didailler C, Rouset-rouvière C, Ryckewaert A, Nobili F, Gindre FA, Rambaud J, Duncan A, Berthiller J, Bacchetta J, Sellier-leclerc A. Cardiac involvement in pediatric hemolytic uremic syndrome. Pediatr Nephrol. [DOI: 10.1007/s00467-022-05427-2] [Reference Citation Analysis]
6	Travert B, Rafat C, Mariani P, Cointe A, Dossier A, Coppo P, Joseph A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management. Toxins (Basel) 2021;13:306. [PMID: 33925836 DOI: 10.3390/toxins13050306] [Reference Citation Analysis]
7	Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91. [PMID: 28899876 DOI: 10.1136/archdischild-2016-311377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]